Aloxistatin

For research use only. Not for therapeutic Use.

  • CAT Number: I005308
  • CAS Number: 88321-09-9
  • Molecular Formula: C17H30N2O5
  • Molecular Weight: 342.40
  • Purity: ≥95%
Inquiry Now

Aloxistatin(Cat No.:I005308), also known as E-64d, is a potent, cell-permeable cysteine protease inhibitor, widely utilized in research for its ability to inhibit enzymes like cathepsins B, H, and L. By preventing the degradation of cellular components, Aloxistatin aids in studying protease functions in various biological processes, including autophagy and cell death. Its specificity for cysteine proteases makes it a valuable tool in studying diseases associated with excessive protease activity, such as cancer and neurodegenerative disorders. Aloxistatin’s stability and selectivity support its use in protease-related research and therapeutic exploration.


Catalog Number I005308
CAS Number 88321-09-9
Synonyms

ethyl (2S,3S)-3-[[(2S)-4-methyl-1-(3-methylbutylamino)-1-oxopentan-2-yl]carbamoyl]oxirane-2-carboxylate

Molecular Formula C17H30N2O5
Purity ≥95%
Target Cathepsin
Solubility DMSO: ≥ 23 mg/mL
Storage Store at -20°C
IUPAC Name ethyl (2S,3S)-3-[[(2S)-4-methyl-1-(3-methylbutylamino)-1-oxopentan-2-yl]carbamoyl]oxirane-2-carboxylate
InChI InChI=1S/C17H30N2O5/c1-6-23-17(22)14-13(24-14)16(21)19-12(9-11(4)5)15(20)18-8-7-10(2)3/h10-14H,6-9H2,1-5H3,(H,18,20)(H,19,21)/t12-,13-,14-/m0/s1
InChIKey SRVFFFJZQVENJC-IHRRRGAJSA-N
SMILES CCOC(=O)[C@@H]1[C@H](O1)C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C
Reference

<p style=/line-height:25px/>
<br>[1]. Doh-Ura K, et al. Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J Virol. 2000 May;74(10):4894-7.
https://www.ncbi.nlm.nih.gov/pubmed/10775631
<br>[2]. Konjar S, et al. Human and mouse perforin are processed in part through cleavage by the lysosomal cysteine proteinase cathepsin L. Immunology. 2010 Oct;131(2):257-67.
https://www.ncbi.nlm.nih.gov/pubmed/20497254
<br>[3]. Mullins SR, et al. Three-dimensional cultures modeling premalignant progression of human breast epithelial cells: role of cysteine cathepsins. Biol Chem. 2012 Dec;393(12):1405-16.
https://www.ncbi.nlm.nih.gov/pubmed/23667900
<br>[4]. Hook G, et al. The cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in Alzheimer/’s disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activity. J Alzheimers Dis. 2011;26(2):387-408.
https://www.ncbi.nlm.nih.gov/pubmed/21613740
<br>[5]. Cheng XW, et al. Superoxide-dependent cathepsin activation is associated with hypertensive myocardial remodeling and represents a target for angiotensin II type 1 receptor blocker treatment. Am J Pathol. 2008 Aug;173(2):358-69.
https://www.ncbi.nlm.nih.gov/pubmed/18583318
?
</p>

Request a Quote